Open Payments

TEI Biosciences Inc

Payments to physicians and teaching hospitals reported to CMS under the Sunshine Act for 2019. Data sourced directly from the Open Payments federal database.

Program year 2019
5 recipients
$335
Total Paid (2019)
to 5 doctors
$335
Total Paid
2019 program year
5
Physicians Paid
individual recipients
$67
Avg per Physician
mean payment
Payments from industry are legal under federal law and do not indicate wrongdoing. Approximately 57% of US physicians receive some form of industry payment. Learn how to interpret this data →

Top Recipients — TEI Biosciences Inc

Open Payments 2019
Physician Specialty Location Amount Received
HORNE, AARON MD — NJ $114
PERRY, ADAM MD — NJ $95
MENACK, MICHAEL M.D. — NJ $55
KAUL, SANJEEV MD — NJ $42
RENZA-STINGONE, ELIZABETH MD — NJ $30
Browse all
All Companies
Search other pharma and device company payments
Context
Understanding Open Payments
What these payments mean and what to ask your doctor
Data source
Methodology
How we process and present CMS Open Payments data
Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →